Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Feasibility of alpha-emitting radium-223 in skeletal metastases therapy examined
August 11th, 2005
Scientists discussed the feasibility of alpha-emitting radium-223 (Ra-223) in the treatment of skeletal metastases from breast cancer. According to a study from Norway, "The main goals were to study the safety and tolerability of the alpha-emitter Ra-223 in breast and prostate cancer patients with skeletal metastases. In addition, pain palliation was evaluated." "Fifteen prostate and 10 breast cancer patients enrolled in a phase I trial received a single I.V. injection of Ra-223. Five patients were included at each of the dosages: 46, 93, 163, 213, or 250 kBq/kg and followed for 8 weeks. Palliative response was evaluated according to the pain scale...
Source: Women's Health Weekly (2005-08-11)
|
